Announcements Trials
Browse Landscape

Phase

Phase 3 5Phase 1/2 2Phase 2/3 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia 1Congenital Abnormalities 1

Interventions

Cytarabine 116Cyclophosphamide 104venetoclax 89fludarabine 85Azacitidine 81fludarabine phosphate 70Rituximab 59Filgrastim 44Peripheral Blood Stem Cell Transplantation 39Methotrexate 39Dexamethasone 35Decitabine 35Busulfan 32Etoposide 31Tacrolimus 30Mycophenolic Acid 29Granulocyte Colony-Stimulating Factor 28Lenalidomide 27Whole-Body Irradiation 26Idarubicin 26Vincristine 25Melphalan 24Cyclosporine 24Clofarabine 24Mitoxantrone 22Bortezomib 21Alemtuzumab 21ibrutinib 19ruxolitinib 17aldesleukin 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Amsacrine × Other hematologic neoplasm × Clear all
NCT05807932 2024-05-01

Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML

Heinrich-Heine University, Duesseldorf

Phase 1/2 Recruiting
38 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT00840684 2011-05-13

Laromustine, Daunorubicin, and Cytarabine in Treating Patients With Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 1/2 Completed
135 enrolled
Other hematologic neoplasm

Congenital Abnormalities, Leukemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡